TAT-CF Final Conference: “Research and new treatments in Cystic Fibrosis”

The University of Burgos (UBU), in collaboration with the National Reference Centre for People with Rare Diseases (CREER), will hold the TAT-CF final conference on 4th December in Burgos. This conference is aimed at associations and patients, as well as professionals in the sector and the objectives are to present the main results obtained within the TAT-CF project and establish a debate on the therapeutic advances that are currently being made in the field of Cystic Fibrosis. We will have the pleasure of hosting several renowned experts in the area, which will give an overview of new research and treatments related to this disease.

The event will be broadcast live to allow a wider participation.
For more information and register, please visit: https://www.ubu.es/te-interesa/jornada-investigacion-y-nuevos-tratamientos-en-fibrosis-quistica.

This conference will be organized along with the final TAT-CF workshop (Monday, 3rd December) and the Steering Committee meeting (Wednesday, 5th December).

Agenda

09:30: Welcome

09:45 – 10:00: Opening

Mr. Aitor Aparicio García. General Manager –CREER–.

Mr. José Miguel García Pérez. Vice-chancellor of Research and Knowledge Transfer –UBU–.

10:00 – 10:30: “CF genetics and new treatments

Carmen Prior. Institute of Medical and Molecular Genetics –INGEMM–; La Paz University Hospital (Spain).

10:30 – 11:00: “CFTR modulators and Cystic Fibrosis”

Pedro Mondéjar López. Virgen de la Arrixaca Clinic University Hospital –HCUVA– (Spain).

11:00 – 11:30: “Pharmacological strategies for the correction of the basic defect in Cystic Fibrosis”

Luis Galietta. Telethon Institute of Genetics and Medicine –TIGEM– (Italy).

11:30 – 12:00: Coffee break

12:00 – 12:30: TAT-CF project “Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters”

Roberto Quesada. University of Burgos –UBU– (Spain).

12:30 – 13:00: “New drugs development: from research to commercialization”

Ángel del Pozo. Praxis Pharmaceutical S.A. –BIOPRAXIS– (Spain).

13:00 – 13:40: “Technological advances in the detection and monitoring of CF”

  • Application of new technologies to health: MyCyFAAP.

Joaquim Calvo.  Health Research Institute Hospital La Fe – IISLAFE– (Spain).

  • Polymeric chemosensor for the detection and quantification of chloride in human sweat and its application to the diagnosis of cystic fibrosis.

Saúl Vallejos. University of Burgos –UBU– (Spain).

13:40 – 14:00: Questions

14:00: End of the conference